<DOC>
	<DOC>NCT01146938</DOC>
	<brief_summary>To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers</brief_summary>
	<brief_title>A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>&lt;Hepatic impairment patient&gt; age: 20 64 years sex: male ChildPugh score A or ChildPugh score B body weight: greater than 55 kg written informed consent &lt;Healthy volunteer&gt; age: 20 64 years sex: male body weight: greater than 55 kg written informed consent &lt;Hepatic impairment patient&gt; portosystemic shunt surgery ChildPugh score C creatinine clearance &lt; 80mL/min ascites &lt;Healthy volunteer&gt; AST(SGOT), ALT(SGPT) &gt; 1.5 times of Upper Normal Range Total bilirubin &gt; 1.5 times of Upper Normal Range positive drug or alcohol screening</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>fimasartan</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>